Know Cancer

or
forgot password

An Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine (C11 MET) in Prostate Cancer, as Assessed by Positron Emission Tomography (PET)


N/A
18 Years
N/A
Not Enrolling
Male
Prostate Cancer

Thank you

Trial Information

An Evaluation of the Effects of Chemotherapy on the Uptake and Retention of Carbon 11 Methionine (C11 MET) in Prostate Cancer, as Assessed by Positron Emission Tomography (PET)


In the week before the patients first dose of chemotherapy they will receive a C11
methionine PET scan which takes about 90 minutes. C11 methionine is a radioactively labeled
amino acid that is given to the patient intravenously.

Eighteen to twenty days after the patients first dose of docetaxel chemotherapy, they will
have another C11 methionine PET scan which is identical to the first scan.

At the end of three cycles of docetaxel chemotherapy (about 2 and 1/2 months on study)
another C11 methionine PET scan will be done.

The PET scans will show how well the tumor is taking up methionine.


Inclusion Criteria:



- Metastatic hormone-refractory prostate cancer patients who are planned to begin every
3-week docetaxel chemotherapy

- Progression after androgen deprivation therapy

- Serum testosterone < 50ng/ml

- 18 years of age or older

Exclusion Criteria:

- Prior taxane therapy

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

To describe the association between percent change in tumor standardized uptake value (SUV) after c11 methionine administration after one cycle of every three-week docetaxel-based chemotherapy and prostate-specific antigen (PSA) response

Principal Investigator

Robert Ross, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Dana-Farber Cancer Institute

Authority:

United States: Institutional Review Board

Study ID:

04-419

NCT ID:

NCT00139204

Start Date:

April 2005

Completion Date:

July 2006

Related Keywords:

  • Prostate Cancer
  • Prostate cancer
  • Hormone-refractory prostate cancer
  • PET scan
  • C11-methionine
  • positron emission tomography
  • Prostatic Neoplasms

Name

Location
Beth Israel Deaconess Medical Center Boston, Massachusetts  02215
Dana-Farber Cancer Institute Boston, Massachusetts  02115
Massachusetts General Hospital Boston, Massachusetts  02114-2617